ASH 2024 | Improving the sensitivity of MRD assessment in AML: multi-omic characterization of progenitor cells
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, comments on the limitations of flow cytometry in assessing measurable residual disease (MRD) in acute myeloid leukemia (AML) compared with other hematological malignancies. Dr Paiva highlights that the lack of knowledge on specific markers expressed in AML blasts has hindered the development of more comprehensive MRD assessment panels, but a multi-omic characterization of progenitor cells has identified new candidate markers which have improved the sensitivity of MRD assessment in a series of 100 patients. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI generated)
We are seeing that, at least in the flow cytometry field, that AML, in terms of MRD assessment, is lagging behind when compared to other hematological malignancies such as CLL or multiple myeloma. And the reason is because we lack knowledge in terms of markers that are apparently expressed in blasts to implement these in more comprehensive panels, also leveraging on more sophisticated instruments that are now available to perform flow cytometry...
We are seeing that, at least in the flow cytometry field, that AML, in terms of MRD assessment, is lagging behind when compared to other hematological malignancies such as CLL or multiple myeloma. And the reason is because we lack knowledge in terms of markers that are apparently expressed in blasts to implement these in more comprehensive panels, also leveraging on more sophisticated instruments that are now available to perform flow cytometry. Now this was the reason why we performed the multi-omic characterization of progenitor cells from patients with AML compared to healthy adults and using this strategy we found new candidate markers that could be informative. Markers such as CD45RA, CD69, CD25. And these were implemented in larger panels that were prospectively used in a series of 100 patients with AML and we showed that using this strategy we were able to increase the sensitivity of MRD assessment. Importantly, also to have a better picture of how much dysplasia there was regardless of the detection of MRD and how this was complementary on top of MRD to better stratify relapse-free survival.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
